Press Releases
August 30, 2024
HOOKIPA Pharma Announces Board of Directors Changes
August 28, 2024
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
August 8, 2024
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
July 22, 2024
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 8, 2024
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 1, 2024
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
June 4, 2024
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
May 30, 2024
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
May 23, 2024
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 9, 2024
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
April 25, 2024
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 24, 2024
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 16, 2024
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
March 22, 2024
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 6, 2024
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
January 29, 2024
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 16, 2024
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization